Bio-Rad Announces the Release of Liquichek™ Maternal Serum II Control
The multi-constituent control offers increased efficiency and confidence in test results
6 Jun 2016
Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, announces the release of Liquichek Maternal Serum II Control, a frozen liquid human serum-based material designed to monitor the precision of laboratory test procedures used during maternal serum second trimester screening.
Liquichek Maternal Serum II Control includes AFP, Free Estriol, hCG and Inhibin A, making it ideal for laboratories performing triple or quadruple marker screening. The liquid form eliminates the need for reconstitution, increasing efficiency and allowing samples to be treated the same way as patient specimens. As an independent quality control, Liquichek Maternal Serum II Control is not optimized for a specific test system and provides laboratories greater confidence in patient results.
Key Benefits
Liquichek Maternal Serum II Control is a multi-constituent control:
- Designed for use on various instruments and reagent systems
- Offer three-year shelf life when stored at -20 to -70°C and open-vial stability of 30 days when stored between 2°C to 8°C
- Available in three individual levels
When used with Bio-Rad’s Unity™ Interlaboratory Program, the world’s largest comparison peer group and Unity Real Time®, an expert data management software solution designed to improve the effectiveness of quality control processes, maternal serum testing laboratories are provided with the industry’s most complete solution for daily, optimized quality controls. In addition, Unity Interlaboratory Program participants are able to access their reports online at QCNet™.